Authors
Latest:
Wheatley and Gopalsami Highlight the Value of Interdisciplinary Collaboration in HSCT CareTia Wheatley, DNP, RN, AOCNS, BMTCN, and Shivani Gopalsami, RN, MSN, ANP-BC, AOCNP, discuss the benefits and challenges of multidisciplinary collaboration in hematopoietic stem cell transplant care.
Latest:
Caring for an Immunocompromised Bone Marrow Transplant RecipientSpecial protocols are required to ensure the safety of patients undergoing bone marrow transplants.
Latest:
The Importance of Quality of Life in Bladder CancerIn the April 2024 issue of Oncology Nursing News, stories focus on bladder-preserving treatment options in bladder cancer, recent FDA approvals, conference news, and embracing vicarious resilience.
Latest:
Empower Your Clinical Staff to Meet the Growing Patient VolumeOncology practices can create more access to care by leveraging the use of APPs, empowering nurses to practice at the top of their licensure, utilizing nurse navigators, and planning ahead.
Latest:
Older Patients Are Comfortable With Telehealth and Prefer It as an Option92% of those over 70 say they are comfortable with telehealth.
Latest:
Key Takeaways for Patients With MyelofibrosisPatients with myelofibrosis should reflect on their personal priorities and quality of life goals, understand the range of available JAK inhibitor treatment options, and openly communicate with their doctor to arrive at a shared decision for managing their disease.
Latest:
Heather Niccum Haag on Improving Patient Education With BelzutifanHeather Niccum Haag, BSN, RN, CCRN, shares her experience creating an educational resource for her patients with Von-Hippel Lindau tumors who are receiving belzutifan.
Latest:
Advanced Practice Providers Are Uniquely Suited for Survivorship CareAdvanced practice providers are the future of survivorship care because of the tremendous value they offer to the practice and its patients.
Latest:
Idecabtagene Vicleucel Approved by FDA in R/R Multiple MyelomaThe FDA has approved idecabtagene vicleucel for patients with relapsed/refractory multiple myeloma who have received 2 prior lines of therapy.
Latest:
Global Study Suggests More Informational Resources Needed for Renal Cell CarcinomaA global study revealed that patients and caregivers alike reported insufficient knowledge surrounding renal cell carcinoma.
Latest:
Caring for a Patient Undergoing CAR T-Cell Therapy for Relapsed/Refractory Multiple MyelomaThe introduction of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma is considered one of the most significant advancements in the past decade.
Latest:
Prescribing 20 mg of Mozart for Chemotherapy-Induced NauseaA Michigan State University investigator is preparing to expand on an encouraging pilot study that used a music-listening intervention to influence chemotherapy-induced nausea.
Latest:
5 Media Tips and Tricks For Health Care ProfessionalsHeather Simonsen, MA, outlines some ways for health care professionals to feel more comfortable in the spotlight.
Latest:
Oncology Drug Crash Course: Teclistamab-cqyv (Tecvayli)Amanda Warner, MS, BSN, RN, OCN, who is manager of research informatics & real world evidence with Florida Cancer Specialists & Research Institute, provides an in-depth look at teclistamab in a downloadable fact sheet.
Latest:
Datopotamab Deruxtecan Demonstrates Manageable Safety Profile in TNBCCompared with other antibody-drug conjugates, datopotamab deruxtecan was associated with lower rates of neutropenia, pneumonitis, and hematologic toxicity.
Latest:
Rx Road Map: Adagrasib (Krazati)Dawn Landolph, RN, BSN, OCN, MPA, provides an in-depth look at adagrasib for the treatment of patients with KRAS G12C-mutated, locally advanced or metastatic non-small cell lung cancer in a downloadable reference sheet.
Latest:
Talking With Patients About Potential Cancer MisinformationOncology nurses can help their patients navigate misinformation that they may find online.
Latest:
Top Executives Vow to Improve Health Disparities among Patients with Multiple MyelomaOncology nurses are often the main point of contact for newly diagnosed patients with cancer. We have the opportunity to ensure that each person starts their journey with equality and equity on their side.
Latest:
Chemotherapy Plus Endocrine Therapy Increases Cognitive Impairment in Breast CancerPatients with breast cancer may be at risk for more intense cognitive impairment following treatment with chemotherapy plus endocrine therapy.
Latest:
Hilda Haynes-Lewis and Rosaleen Bloom on Financial Toxicity and Workplace Stressors for Patients Undergoing RadiationHilda Haynes-Lewis, PhD, ANP-BC, AOCNP; and Rosaleen Bloom PhD, APRN, ACNS-BC, AOCNS, discuss the ways a cancer diagnosis can impair an individual’s ability to work normally.
Latest:
Study suggests Lymphoma Patients With Depression or Anxiety Experience Shorter Survival TimesPatients with depression had a 37% higher risk of dying from their disease than patients without a mental health diagnosis.
Latest:
Karmanos nurse wins MDONS Outstanding Oncology Nurse of the Year AwardAgnes Pilecki, BSN, RN, a nurse on Barbara Ann Karmanos Cancer Institute’s bone marrow transplant unit, has been named the Metro Detroit Oncology Nursing Society’s (MDONS) Outstanding Oncology Nurse of the Year.
Latest:
Approach Health Disparities From All AnglesApril is National Minority Health Month, highlighting the need for health care and community sectors to come together and improve cancer outcomes for underserved populations.
Latest:
Reanne Booker on Factors to Consider When Discussing Palliative RadiationReanne Booker, MN, NP, highlights factors that make a patient a good candidate for palliative radiation.
Latest:
Care Management Tools Can Mitigate Clinician BurnoutAlthough technology alone can’t solve clinician burnout, it can provide the means for organizations to provide better care while increasing efficiency and alleviating stress.
Latest:
Paula Anastasia on PARP Inhibitor Ineligibility Factors for Women With Ovarian CancerPaula Anastasia, RN, MN, AOCN, highlights circumstances in which patients may not be eligible to receive benefit with a PARP inhibitor.
Latest:
Ruxolitinib Plus Belumosudil Confers a 55% Response Rate in GVHDPatients with GVHD treated with ruxolitinib plus belumosudil experienced an overall response rate of 55%, which may suggest an interaction between inflammatory pathways.
Latest:
Cheryl VerStrate on the Pitfalls of Direct-to-Consumer Genetic TestsCheryl VerStrate, DNP, AGPCNP-BC, OCN, discusses why nurses should be prepared to discuss direct-to-consumer genomic testing with their patients.
Latest:
Tamibarotene-Based Combo Receives Fast Track Designation from the FDA for AMLThe FDA granted tamibarotene plus azacitidine and venetoclax fast track designation for the treatment of newly diagnosed, unfit, RARA-overexpressed AML.
